Sleep-health company SomnoMed (ASX:SOM) has been in focus as investors weigh a tempered FY26 Revenue outlook, a Leadership change and a new product launch ahead of the company’s full-year results. SomnoMed, which makes oral devices for treating obstructive sleep apnoea (OSA), has been navigating a period of transition
Latest News
This content is provided by Exco Player and may use cookies or similar technologies. Please click ‘Allow and Continue’ below to load the content
The Defense Health Agency has explicitly established a hormone-screening pathway for female service members, directing providers to screen women annually for hormonal dysregulation and establishing clinical pathways for problems ranging from menstrual irregularities and fatigue to perimenopause and menopause
Women are posing as men to buy testosterone from online pharmacies because of difficulties getting NHS prescriptions in Wales, according to a consultant
Plenty of people reach 50 and start counting the years until they can stop working. Their sleep is already part of that count
July 14, 2025 ByRachael Moeller Gorman, Health Writer
A study led by researchers at Stanford Medicine shows that differences in blood sugar responses to certain carbohydrates depend on details of an individual’s metabolic health status
Trending
(WDBJ) – A study in the United Kingdom found that AI chatbots gave dangerous medical advice to sleep apnea patients. In a third of cases, chatbots wrongly told patients that their symptoms were not serious, which experts warn could discourage them from seeing a specialist. Researchers said if a patient is already reluctant to see…